Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 10,185 Avalo Therapeutics, Inc. shares (Form 4)

Traded Sep 10, 2026 · Filed Sep 11, 2026

On Sep 10, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 10,185 Avalo Therapeutics, Inc. shares at US$17.62 for US$179K under a trading plan, leaving 39,900 shares. Filed Sep 11, 2026 (Form 4).

Sold
10,185 shares
Price
US$17.62
Value
US$179K
Holding after
39,900 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Sep 10, 2026Common StockOption exercise10,185US$8.0450,085Direct
Sep 10, 2026Common StockSale10,185US$17.6239,900Direct

Source

View original at SEC

Related